Literature DB >> 21504522

Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database.

Ronen Arnon1, Rachel Annunziato, Tamir Miloh, Melissa Wasserstein, Hiroshi Sogawa, Monique Wilson, Frederick Suchy, Nanda Kerkar.   

Abstract

Patients with HT-1 can develop progressive liver disease and have a high incidence of HCC. LT is indicated in patients with fulminant liver failure, HCC or decompensated chronic liver disease refractory to NTBC. To determine the need for LT and outcomes after LT in children with HT-1. Children with HT-1 who had LT between 10/1987 and 5/2008 were identified from the UNOS database. Of 11,467 children in the UNOS database, 125 (1.1%) required LT secondary to HT-1. Mean age at LT was two and half yr (s.d. ± 3.6 yr). Mean age at LT during the first 10 yr of the study (1.82, s.d. ± 2.86 yr) was significantly lower than in the last decade (3.70, s.d. ± 4.42 yr), p = 0.01. Nearly half of the patients (58, 46.4%) were transplanted between 1988 and 1992. Overall, one- and five-yr patient survival was 90.4% and 90.4%, respectively. LT is a valuable option for children with HT-1 with fulminant liver failure or when medical treatment fails. The rate of LT for children with HT-1 has decreased and age at transplant increased over the last decade most probably reflecting the effect of early diagnosis and treatment with NTBC.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 21504522     DOI: 10.1111/j.1399-3046.2011.01497.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  8 in total

1.  Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.

Authors:  Víctor R De Jesús; Barbara W Adam; Daniel Mandel; Carla D Cuthbert; Dietrich Matern
Journal:  Mol Genet Metab       Date:  2014-07-17       Impact factor: 4.797

2.  Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.

Authors:  David C Bartlett; Carla Lloyd; Patrick J McKiernan; Phil N Newsome
Journal:  J Inherit Metab Dis       Date:  2014-02-11       Impact factor: 4.982

3.  Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.

Authors:  David C Bartlett; Mary Anne Preece; Elisabeth Holme; Carla Lloyd; Phil N Newsome; Patrick J McKiernan
Journal:  J Inherit Metab Dis       Date:  2012-03-29       Impact factor: 4.982

4.  Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era.

Authors:  Essam M Imseis; John S Bynon; Chad Thornhill
Journal:  World J Hepatol       Date:  2017-03-28

5.  A case report of two siblings with hypertyrosinemia type 1 presenting with hepatic disease with different onset time and severity.

Authors:  Kazuo Kawabata; Jun Kido; Takanobu Yoshida; Shirou Matsumoto; Kimitoshi Nakamura
Journal:  Mol Genet Metab Rep       Date:  2022-07-01

6.  Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation.

Authors:  Seyed Mohsen Dehghani; Mahmood Haghighat; Mohammad Hadi Imanieh; Hossein Karamnejad; Abdorrasoul Malekpour
Journal:  Int J Prev Med       Date:  2013-12

Review 7.  Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.

Authors:  Julia Geppert; Chris Stinton; Karoline Freeman; Hannah Fraser; Aileen Clarke; Samantha Johnson; Paul Sutcliffe; Sian Taylor-Phillips
Journal:  Orphanet J Rare Dis       Date:  2017-09-11       Impact factor: 4.123

Review 8.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.